Skip to main content
Domnica Luca AG Kato

News categories: Publication

Dysregulation of T cell homeostasis

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

The research team of Prof. Dr. Hiroki Kato at the Institute of Cardiovascular Immunology is dedicated to understanding the intricate mechanisms of immune responses in the context of viral infections and autoimmune diseases. They are particularly interested in exploring how cytoplasmic RNA sensors, like MDA5, differentiate between viral RNAs and self-RNAs, initiating type I interferons (IFNs) as anti-viral defense. However, mutations in MDA5 can lead to autoimmune diseases. Complementary to that, Domnica Luca et al. recently published her findings in Science Advances with the title "Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling."


Abstract: ADAR1 deficiency constitutively activates MDA5 and causes type I IFN-driven autoimmune diseases. We found a significant reduction in the regulatory T cell (Treg) population in patients with type I interferonopathies caused by mutations in the ADAR1 or IFIH1 gene, encoding MDA5. We analyzed the underlying mechanisms using murine models and found that Treg-specific Adar1 deletion caused peripheral Treg loss and scurfy-like lethal autoimmune disorders. Treg-specific expression of MDA5 gain-of-function mutant also reduced the peripheral Treg population via apoptosis, resulting in severe autoimmune symptoms. However, shut-down of MDA5 signaling in Adar1-deficient Tregs still induced eIF-2α-mediated protein synthesis shut-off, leading to Treg loss and lethality. Altogether, our results highlight the dysregulation of Treg homeostasis in Adar1 deficiency as a key determinant for type I interferonopathies.

Publication:

Luca, D., et al. (2024)

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

Science Advances

DOI: 10.1126/sciadv.adk0820

Related news

Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry
Nora Möhn

News categories: Publication

New Findings on Immunotherapy for a Rare Brain Infection

Progressive multifocal leukoencephalopathy (PML) is a rare but very serious brain disease. It is caused by the reactivation of the widespread JC virus when the immune system is severely weakened. There is currently no targeted antiviral therapy available, which is why new treatment approaches are urgently needed. In recent years, so-called immune checkpoint inhibitors have been increasingly used; these “unlock” the immune system and reactivate the body’s own immune cells. The results were recently published in the journal JAMA Neurology.
View entry

Back to the news overview